Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) EBIT: 2018-2021

Historic EBIT for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2021 value amounting to -$26.1 million.

  • Black Diamond Therapeutics' EBIT fell 12.50% to -$26.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$115.3 million, marking a year-over-year decrease of 65.79%. This contributed to the annual value of -$126.9 million for FY2021, which is 82.37% down from last year.
  • Black Diamond Therapeutics' EBIT amounted to -$26.1 million in Q4 2021, which was up 26.25% from -$35.4 million recorded in Q3 2021.
  • Black Diamond Therapeutics' EBIT's 5-year high stood at -$3.0 million during Q4 2018, with a 5-year trough of -$35.4 million in Q3 2021.
  • Its 3-year average for EBIT is -$17.4 million, with a median of -$15.0 million in 2020.
  • Data for Black Diamond Therapeutics' EBIT shows a maximum YoY plummeted of 239.59% (in 2019) over the last 5 years.
  • Over the past 4 years, Black Diamond Therapeutics' EBIT (Quarterly) stood at -$3.0 million in 2018, then plummeted by 239.59% to -$10.3 million in 2019, then tumbled by 124.12% to -$23.2 million in 2020, then declined by 12.50% to -$26.1 million in 2021.
  • Its last three reported values are -$26.1 million in Q4 2021, -$35.4 million for Q3 2021, and -$30.7 million during Q2 2021.